- Home
- STI vs SNSE Comparison
STI vs SNSE Comparison
Compare STI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- SNSE
- Stock Information
- Founded
- STI 2014
- SNSE 2005
- Country
- STI United States
- SNSE United States
- Employees
- STI N/A
- SNSE N/A
- Industry
- STI
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- SNSE Health Care
- Exchange
- STI NYSE
- SNSE Nasdaq
- Market Cap
- STI 9.5M
- SNSE 10.8M
- IPO Year
- STI N/A
- SNSE 2021
- Fundamental
- Price
- STI $4.50
- SNSE $6.98
- Analyst Decision
- STI
- SNSE Strong Buy
- Analyst Count
- STI 0
- SNSE 3
- Target Price
- STI N/A
- SNSE $86.67
- AVG Volume (30 Days)
- STI 60.8K
- SNSE 9.3K
- Earning Date
- STI 08-12-2025
- SNSE 08-05-2025
- Dividend Yield
- STI N/A
- SNSE N/A
- EPS Growth
- STI N/A
- SNSE N/A
- EPS
- STI 6.72
- SNSE N/A
- Revenue
- STI N/A
- SNSE N/A
- Revenue This Year
- STI N/A
- SNSE N/A
- Revenue Next Year
- STI N/A
- SNSE N/A
- P/E Ratio
- STI $0.67
- SNSE N/A
- Revenue Growth
- STI N/A
- SNSE N/A
- 52 Week Low
- STI $2.94
- SNSE $5.00
- 52 Week High
- STI $55.00
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- STI 51.66
- SNSE 36.47
- Support Level
- STI $4.22
- SNSE $7.62
- Resistance Level
- STI $5.59
- SNSE $8.42
- Average True Range (ATR)
- STI 0.41
- SNSE 0.61
- MACD
- STI 0.01
- SNSE -0.23
- Stochastic Oscillator
- STI 24.78
- SNSE 9.13
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a IP leader in both the high-capacity anode and the high-energy solid-state battery.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).